- Home
- MUJ vs CSTL Comparison
MUJ vs CSTL Comparison
Compare MUJ & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MUJ
- CSTL
- Stock Information
- Founded
- MUJ 1998
- CSTL 2007
- Country
- MUJ United States
- CSTL United States
- Employees
- MUJ N/A
- CSTL N/A
- Industry
- MUJ Investment Bankers/Brokers/Service
- CSTL Medical Specialities
- Sector
- MUJ Finance
- CSTL Health Care
- Exchange
- MUJ Nasdaq
- CSTL Nasdaq
- Market Cap
- MUJ 580.8M
- CSTL 555.8M
- IPO Year
- MUJ N/A
- CSTL 2019
- Fundamental
- Price
- MUJ $11.09
- CSTL $20.09
- Analyst Decision
- MUJ
- CSTL Strong Buy
- Analyst Count
- MUJ 0
- CSTL 6
- Target Price
- MUJ N/A
- CSTL $37.67
- AVG Volume (30 Days)
- MUJ 108.0K
- CSTL 702.0K
- Earning Date
- MUJ 01-01-0001
- CSTL 08-04-2025
- Dividend Yield
- MUJ 4.36%
- CSTL N/A
- EPS Growth
- MUJ N/A
- CSTL N/A
- EPS
- MUJ N/A
- CSTL N/A
- Revenue
- MUJ N/A
- CSTL $346,269,000.00
- Revenue This Year
- MUJ N/A
- CSTL N/A
- Revenue Next Year
- MUJ N/A
- CSTL $1.62
- P/E Ratio
- MUJ N/A
- CSTL N/A
- Revenue Growth
- MUJ N/A
- CSTL 20.40
- 52 Week Low
- MUJ $9.74
- CSTL $14.59
- 52 Week High
- MUJ $11.70
- CSTL $35.84
- Technical
- Relative Strength Index (RSI)
- MUJ 68.14
- CSTL 62.20
- Support Level
- MUJ $10.91
- CSTL $18.99
- Resistance Level
- MUJ $11.13
- CSTL $20.18
- Average True Range (ATR)
- MUJ 0.07
- CSTL 0.95
- MACD
- MUJ 0.03
- CSTL 0.37
- Stochastic Oscillator
- MUJ 91.30
- CSTL 81.57
About MUJ Blackrock MuniHoldings New Jersey Quality Fund Inc.
BlackRock MuniHoldings New Jersey Quality Fund Inc is a closed-end management investment company. The investment objective of the company is to provide shareholders with current income exempt from U.S. federal income tax and New Jersey personal income taxes. The fund invests in a portfolio of long-term, investment-grade New Jersey municipal obligations.
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.